{"id":83012,"date":"2026-05-23T00:18:12","date_gmt":"2026-05-23T00:18:12","guid":{"rendered":"https:\/\/www.europesays.com\/people\/83012\/"},"modified":"2026-05-23T00:18:12","modified_gmt":"2026-05-23T00:18:12","slug":"longevity-startup-retro-biosciences-says-latest-fundraise-values-it-at-1-8-billion","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/people\/83012\/","title":{"rendered":"Longevity startup Retro Biosciences says latest fundraise values it at $1.8 billion"},"content":{"rendered":"<p class=\"author-bio\">Allison covers what hot startups are getting up to, and who\u2019s financing them. She is also co-host of the weekly biotech podcast, \u201c<a href=\"https:\/\/www.statnews.com\/category\/readout-loud\/\" rel=\"nofollow noopener\" target=\"_blank\">The Readout Loud<\/a>.\u201d You can reach Allison on Signal at AllisonDeAngelis.01.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/12\/03\/aging-startup-retro-bio-chases-5-billion-valuation\/\" rel=\"nofollow noopener\" target=\"_blank\">Retro Biosciences<\/a>, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday.\u00a0<\/p>\n<p>Retro has a big mission: Add 10 healthy years to the human lifespan. It is seeking to do that by using a variety of technologies, including in vivo gene therapies, cell replacement therapies, and other approaches to spur younger, healthier cells into aging tissues.\u00a0<\/p>\n<p>The company is currently running its first clinical trial \u2014 testing a pill designed to enhance the body\u2019s ability to better clear out protein aggregates in patients with Alzheimer\u2019s disease. Retro CEO Joe Betts-LaCroix told the audience at STAT\u2019s <a href=\"https:\/\/www.statnews.com\/stat-summit-west\/\" rel=\"nofollow noopener\" target=\"_blank\">Breakthrough Summit West<\/a> on Tuesday that the trial is going \u201csuper good\u201d and that researchers haven\u2019t seen any dose-limiting toxicities. He said he anticipates releasing some data from the trial around August.\u00a0<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/people\/wp-content\/uploads\/2026\/04\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Allison covers what hot startups are getting up to, and who\u2019s financing them. She is also co-host of&hellip;\n","protected":false},"author":2,"featured_media":83013,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[150],"tags":[26271,2051,6707,581,46084,23878],"class_list":["post-83012","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sam-altman","tag-aging","tag-biotechnology","tag-pharmaceuticals","tag-sam-altman","tag-stat-summit","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@people\/116621024210463628","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/people\/wp-json\/wp\/v2\/posts\/83012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/people\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/people\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/people\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/people\/wp-json\/wp\/v2\/comments?post=83012"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/people\/wp-json\/wp\/v2\/posts\/83012\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/people\/wp-json\/wp\/v2\/media\/83013"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/people\/wp-json\/wp\/v2\/media?parent=83012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/people\/wp-json\/wp\/v2\/categories?post=83012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/people\/wp-json\/wp\/v2\/tags?post=83012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}